Selected article for: "database registry and present study"

Author: Ohadian Moghadam, Solmaz; Abbasi, Behzad; Nowroozi, Ali; Amini, Erfan; Nowroozi, Mohammad Reza; Momeni, Seyed Ali; Niroomand, Hassan
Title: A possible protective role for Bacillus Calmette-Guérin therapy in urinary bladder cancer in the era of COVID-19: a brief report
  • Cord-id: vqumd2b7
  • Document date: 2021_5_31
  • ID: vqumd2b7
    Snippet: Given the systemic immunogenic effects of Bacillus Calmette-Guérin (BCG) therapy in patients with bladder cancer and its non-specific immunogenic effects in viral respiratory diseases, we aimed to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in bladder cancer patients with a history of BCG therapy. In the present study, all bladder cancer survivors with a history of BCG therapy were identified and included in the study according to the data recovered from the UOR
    Document: Given the systemic immunogenic effects of Bacillus Calmette-Guérin (BCG) therapy in patients with bladder cancer and its non-specific immunogenic effects in viral respiratory diseases, we aimed to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in bladder cancer patients with a history of BCG therapy. In the present study, all bladder cancer survivors with a history of BCG therapy were identified and included in the study according to the data recovered from the UORC (Uro-Oncology Research Center) registry database. These patients were followed up in terms of acquiring coronavirus disease 2019 (COVID-19). Among the studied patients, 102 eligible bladder cancer patients with a history of BCG therapy entered the study. The males constituted the majority of the patients (86.3%), and more than half of the study population (55.9%) were above 65 years old. Among the understudy patients, 12.7% were confirmed for COVID-19. The study results did not show a statistically significant association between the time and number of BCG therapy courses and SARS-CoV-2 infection. Although no statistically significant association was observed between receiving BCG therapy and developing COVID-19, the infection rate in patients who had recently received BCG therapy was lower than those who had received therapy more than a year ago.

    Search related documents:
    Co phrase search for related documents
    • low number and lung tissue: 1, 2, 3
    • low number and lung tissue damage: 1
    • low percentage and lung tissue: 1, 2, 3
    • lung tissue and macrophage neutrophil: 1, 2, 3, 4, 5, 6, 7
    • lung tissue damage and macrophage neutrophil: 1, 2